[EFFECT OF ALPHA-METHYLDOPALANINE AND SERYLTRIHYDROXYBENZYLHYDRAZINE (RO 4-4602) ON THE DOPA-DECARBOXYLASE ACTIVITY]. 1965

T L CHRUSCIEL, and S M POJDA

UI MeSH Term Description Entries
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D012106 Research Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed) Research Priorities,Laboratory Research,Research Activities,Research and Development,Activities, Research,Activity, Research,Development and Research,Priorities, Research,Priority, Research,Research Activity,Research Priority,Research, Laboratory
D002262 Carboxy-Lyases Enzymes that catalyze the addition of a carboxyl group to a compound (carboxylases) or the removal of a carboxyl group from a compound (decarboxylases). EC 4.1.1. Carboxy-Lyase,Decarboxylase,Decarboxylases,Carboxy Lyase,Carboxy Lyases
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D001545 Benserazide An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone. Serazide,Seryltrihydroxybenzylhydrazine,DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide,Ro 4-4602,Seryltrihydroxy Benzylhydrazine,Benzylhydrazine, Seryltrihydroxy,Ro 4 4602,Ro 44602

Related Publications

T L CHRUSCIEL, and S M POJDA
November 1972, Nederlands tijdschrift voor geneeskunde,
T L CHRUSCIEL, and S M POJDA
October 1971, Wiener medizinische Wochenschrift (1946),
T L CHRUSCIEL, and S M POJDA
May 1973, The Journal of pharmacy and pharmacology,
T L CHRUSCIEL, and S M POJDA
January 1972, Schweizerische medizinische Wochenschrift,
Copied contents to your clipboard!